This study is currently not recruiting participants.

BO28407; A RANDOMIZED MULTICENTER OPEN-LABEL PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER

Investigating the Efficacy and Safety of Two Treatment Combinations for Breast Cancer

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to evaluate the efficacy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combination with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination with Perjeta and ataxane as adjuvant therapy in patients with HER2-positive primary invasive breast cancer.

Detailed description of study

This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combination with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination with Perjeta and ataxane as adjuvant therapy in patients with HER2-positive primary invasive breast cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effectiveness and safety of two different treatment combinations for patients with HER2-positive primary invasive breast cancer. HER2-positive means that the cancer cells have more HER2 receptors, which can promote the growth of cancer cells. The purpose of this study is to compare an investigational medication combined with another treatment against a different combination that includes a taxane, which is a type of chemotherapy.

Participants in the study will receive one of two treatment combinations. One group will receive an investigational medication along with another treatment, while the other group will receive a different combination that includes a taxane. A taxane is a type of chemotherapy drug that helps stop the growth of cancer cells.

  • Who can participate: Participants must have HER2-positive primary invasive breast cancer. Age criteria not specified.
  • Study details: Participants will be randomly assigned to one of two study arms. One arm will receive an investigational medication combined with another treatment, while the other arm will receive a different combination that includes a taxane.
Updated on 19 Feb 2024. Study ID: 1312111060

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team